Skip to main content

Geron Corp

corporate_fare Company Profile

Geron Corp

GERN·NASDAQ·Life Sciences·CIK 0000886744

We are a commercial-stage biopharmaceutical company focused on treating blood cancer. Our primary product is RYTELO® (imetelstat), a telomerase inhibitor. RYTELO was commercially launched in the U.S. in June 2024, following its approval by the U.S. Food and Drug Administration (FDA) on June 6, 2024. It is approved for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS) who have transfusion-dependent (TD) anemia, requiring four or more red blood cell units over eight weeks, and who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). Lower-risk MDS is a progressive blood cancer where patients often become dependent on red blood cell transfusions. We believe the results of our Phase 3 clinical trial, IMerge, in LR-MDS, along with the FDA label and National Comprehensive Cancer Network (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®), position RYTELO to compete in significant market segments within lower-risk MDS. This includes second-line ESA ineligible patients, regardless of prior treatment or RS status, and first-line ESA ineligible patients. In March 2025, the European Commission (EC) approved RYTELO for adults with TD anemia due to lower-risk MDS without an isolated deletion 5q cytogenetic (non-del 5q) abnormality, who had an unsatisfactory response to or are ineligible for ESAs. RYTELO is the first and only telomerase inhibitor approved by the EC, with marketing authorization covering all 27 European Union member states, Iceland, Norway, and Liechtenstein. We are working to make RYTELO available to eligible LR-MDS patients outside of the U.S., including in the EU.

Geron Corp (NASDAQ:GERN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for GERN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for GERN spans 10-Q, 8-K, DEF 14A, S-3ASR.

Recent high-impact activity:

  • Geron 10-Q: Q3 Profit on $60.1M RYTELO Sales, $339.4M Cash After IMpactMF Wind-Down
  • Geron Swings to Q3 Profit on $60.1M RYTELO Revenue, Cuts 2026 Opex Guidance
  • Geron Swings to Profit as RYTELO Revenue Hits $60.1M, Opex Guidance Cut
  • Geron Scraps Phase 3 Myelofibrosis Trial After DMC Says Survival Endpoint Unlikely
  • Geron Q2 Revenue Jumps 17% to $57.5M; Loss Narrows; Cash Runway Extended

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$83.5M
Diluted EPS
-$0.13
Op. Cash Flow
-$111.04M
Operating Income
-$68.58M
Cash & Equivalents
$77.56M
Total Debt
$119.55M
Debt / Equity
0.53×
Shares Outstanding
639.86M sh
Source: 10-K · filed 2026-03-02 · accession 0000886744-26-000008

Short Interest & Short Volume

3.92 days to cover

FINRA reported short interest of 66,951,283 shares in GERN as of the October 30, 2026 settlement, a 10.3% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 66.7% of GERN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)66,951,283 shares as of October 30, 2026
Change vs prior period▼ 10.3%
Days to cover3.92 at avg daily volume of 17,058,867
Daily short volume (FINRA facilities)66.7% of 8,951,440 shares on November 20, 2026
5-day average short volume57.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with G →
$0.892 +2.45% today
52-week range · as of 2026-11-04 $0.84 – $2.01
Market cap
$560.94M
Volume
13.8M (0.9× avg)
3-mo avg 16.2M
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GERN - Latest Insights

GERN
Nov 04, 2026, 5:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.892 info
Change: -$0.178 (-17%) info
Market Cap: $560.939M info
GERN
Nov 04, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.970
Real-time Price: $0.892 info
Change: -$0.078 (-8%) info
Market Cap: $560.939M info
GERN
Nov 04, 2026, 7:03 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9584
Real-time Price: $0.892 info
Change: -$0.0664 (-7%) info
Market Cap: $560.939M info
GERN
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.15
Real-time Price: $0.892 info
Change: -$0.2578 (-22%) info
Market Cap: $560.939M info
GERN
Aug 05, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.892 info
Change: -$0.708 (-44%) info
Market Cap: $560.939M info
GERN
May 21, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $0.892 info
Change: -$0.358 (-29%) info
Market Cap: $560.939M info
GERN
May 06, 2026, 4:49 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $0.892 info
Change: -$0.688 (-44%) info
Market Cap: $560.939M info
GERN
May 06, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.56
Real-time Price: $0.892 info
Change: -$0.668 (-43%) info
Market Cap: $560.939M info
GERN
May 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $0.892 info
Change: -$0.8073 (-48%) info
Market Cap: $560.939M info
GERN
Apr 07, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $0.892 info
Change: -$0.888 (-50%) info
Market Cap: $560.939M info
GERN
Mar 26, 2026, 8:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.56
Real-time Price: $0.892 info
Change: -$0.668 (-43%) info
Market Cap: $560.939M info
GERN
Mar 02, 2026, 7:47 AM EST
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $0.892 info
Change: -$0.718 (-45%) info
Market Cap: $560.939M info
GERN
Mar 02, 2026, 7:11 AM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.892 info
Change: -$0.738 (-45%) info
Market Cap: $560.939M info
GERN
Feb 25, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.81
Real-time Price: $0.892 info
Change: -$0.918 (-51%) info
Market Cap: $560.939M info
GERN
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.36
Real-time Price: $0.892 info
Change: -$0.468 (-34%) info
Market Cap: $560.939M info
GERN
Jan 06, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.32
Real-time Price: $0.892 info
Change: -$0.428 (-32%) info
Market Cap: $560.939M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets